Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, affects an estimated 10.5 million people worldwide and remains a leading cause of infectious cardiomyopathy in Latin America. One of the most frustrating aspects of managing the infection is its unpredictability: although the parasite persists for life without treatment, only 20 to 30 percent of chronically infected individuals ever move from an asymptomatic state to clinically significant cardiac disease. Clinicians currently have no reliable way to know which patients fall into that minority, and existing antiparasitic drugs are limited by toxicity and variable efficacy.
A new metabolomics study published in Nature Communications reports that circulating small molecules measured in serum may change that picture. The research set out to identify biomarkers capable of predicting progression from asymptomatic infection to cardiac Chagas disease, with the goal of improving clinical risk stratification and supporting the development of new therapies.
The team used untargeted liquid chromatography–mass spectrometry profiling, running samples across complementary chromatographic platforms to capture as broad a chemical landscape as possible. They then applied univariate statistics, machine learning feature selection, and receiver operating characteristic analysis to sift candidate biomarkers out of the resulting data, and validated the leading candidates with targeted analysis.
The search yielded eight individual metabolite biomarkers and 45 combinatorial panels predictive of progression status. Notably, 10 of those panels met the sensitivity and specificity criteria laid out in a target product profile for Chagas disease treatment-response biomarkers, a benchmark suggesting the panels could perform well enough for real clinical use.
The key implication is that metabolites measured at a single baseline time point can predict future cardiac disease progression, rather than merely reflecting damage that has already occurred.
The findings also carry weight for drug development. Because current antiparasitic therapies are limited by toxicity and variable efficacy, the authors note that reliable biomarkers capable of predicting disease progression would support therapeutic development.
The authors describe the work as a foundation for clinically deployable prognostic tools in chronic Chagas disease. The authors describe the work as a foundation for clinically deployable prognostic tools in chronic Chagas disease, and the article notes that this version is subject to further edits and will be replaced by the final Version of Record.
Subject of Research: Serum metabolite biomarkers predicting progression to cardiac Chagas disease
Article Title: Small molecule biomarkers predictive of Chagas disease progression
Article References: Liu, Z., Godinho, J., Laro, J. A., DeToy, K., Vucetic, S., Edens, J. R., Condori, J., Duque, C., Saucedo, G. D., Verastegui, M., Carballo-Jimenez, P., Mercado-Saavedra, B. N., Tinajeros, F., Málaga-Machaca, E. S., Marcus, R., Gilman, R. H., Bowman, N. M., & McCall, L.-I. (2026). Small molecule biomarkers predictive of Chagas disease progression. Nature Communications. https://doi.org/10.1038/s41467-026-78899-7
Image Credits: AI Generated
DOI: 10.1038/s41467-026-78899-7
Keywords: Chagas disease, Trypanosoma cruzi, metabolomics, biomarkers, cardiomyopathy, machine learning, ROC analysis, prognosis, Latin America, serum biomarkers, Small, molecule
News Source: Frances Kline. (October 29, 2026). Blood metabolites may flag who will develop Chagas heart disease. Scienmag.
